Selank (Anxiolytic Nootropic Peptide)

What Is Selank?

Selank (TP-7) is a synthetic heptapeptide developed in the late 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a modified analog of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) that is cleaved from the Fc region of immunoglobulin G (IgG) and plays a key role in innate immune function. The Selank sequence extends tuftsin with a three-amino-acid addition (Pro-Gly-Pro) that stabilizes the molecule against enzymatic degradation and imparts significant anxiolytic and nootropic properties.

Selank was approved for medical use in Russia in 2009 as an anxiolytic and nootropic agent, where it is prescribed under the trade name Selank for generalized anxiety disorder (GAD) and neurasthenia. It represents a class of peptide anxiolytics that offers meaningful advantages over traditional benzodiazepines: it reduces anxiety without causing sedation, cognitive impairment, muscle relaxation, or physical dependence.

The key distinction of Selank is that it achieves anxiolysis through modulation of multiple neurotransmitter systems simultaneously — GABA, serotonin, norepinephrine, and dopamine — without directly binding to and activating GABA-A receptors in the way benzodiazepines do. This broader, gentler mechanism of action underlies its favorable side effect profile.

Mechanism of Action

Tuftsin Foundation

To understand Selank, it is helpful to understand its parent molecule. Tuftsin is an endogenous immunopeptide that:

• Stimulates phagocytosis by macrophages and neutrophils
• Enhances natural killer (NK) cell activity
• Modulates cytokine production
• Plays a role in the brain’s immune-neuroendocrine communication

Tuftsin deficiency (such as after splenectomy, since the spleen is the primary site of tuftsin generation) is associated with increased susceptibility to infections and, interestingly, increased anxiety-like behavior in animal models.

GABA System Modulation

Selank’s anxiolytic effects are primarily mediated through modulation of the GABAergic system:

1. Allosteric modulation of GABA-A receptors: Selank enhances the sensitivity of GABA-A receptors to GABA without directly activating them. This is fundamentally different from benzodiazepines, which directly potentiate GABA-A receptor chloride currents.
2. Increased GABA availability: Selank may inhibit the enzymatic degradation of GABA, increasing synaptic GABA concentrations
3. GABA transporter modulation: Evidence suggests Selank influences GABA reuptake, prolonging GABAergic signaling
4. Subunit selectivity: Unlike benzodiazepines (which act broadly on alpha-1, 2, 3, and 5 subunits), Selank’s effects appear more selective, which may explain the absence of sedation and motor impairment

Serotonin Modulation

Selank influences the serotonergic system in ways that contribute to both its anxiolytic and mood-stabilizing effects:

• Modulation of 5-HT metabolism: Selank affects the expression of enzymes involved in serotonin synthesis and degradation (tryptophan hydroxylase, monoamine oxidase)
• Receptor sensitivity: May alter the sensitivity of 5-HT1A receptors, which are key targets for anxiolytic action
• Gene expression: Studies have shown Selank modulates the expression of over 30 genes related to serotonin signaling

BDNF and Neurotrophic Effects

Selank upregulates brain-derived neurotrophic factor (BDNF) expression, which mediates many of its cognitive-enhancing effects:

• BDNF supports survival and growth of existing neurons
• Nerve growth factor (NGF) upregulation promotes cholinergic neuron health (important for memory)
• Enhanced neuroplasticity through increased dendritic branching and synaptogenesis
• Neuroprotection against oxidative stress and excitotoxicity

These neurotrophic effects take time to manifest, which explains why Selank’s cognitive benefits are cumulative over weeks of use while its anxiolytic effects are more immediate.

Enkephalin System

Selank inhibits the activity of enkephalinase (the enzyme that degrades enkephalins), leading to increased endogenous enkephalin levels. Enkephalins are endogenous opioid peptides that modulate:

• Pain perception
• Emotional responses to stress
• Reward and motivation circuits
• Anxiety and fear responses

This mechanism contributes to Selank’s anxiolytic and mild mood-elevating effects without the addiction potential of exogenous opioids, because the increase in enkephalins is modest and physiological rather than pharmacological.

Immune Modulation

Inherited from its tuftsin parent, Selank retains significant immunomodulatory activity:

• Enhanced phagocyte activity: Increased pathogen clearance by macrophages
• Cytokine balance: Modulation of IL-6, TNF-alpha, and interferon production
• NK cell activation: Enhanced innate antiviral immunity
• Anti-inflammatory effects: Reduction of excessive inflammatory signaling

This immune component is unique among anxiolytic compounds and may contribute to the overall improvement in well-being reported by users, particularly those with chronic stress (which is immunosuppressive).

Clinical Research

Russian Clinical Trials

Selank has undergone extensive clinical testing in Russia, including:

Generalized Anxiety Disorder (GAD):

• A randomized, double-blind, placebo-controlled study of 62 patients with GAD showed that Selank (intranasal, 3 times daily for 14 days) produced significant reduction in Hamilton Anxiety Scale scores compared to placebo
• Anxiolytic effects were comparable to medazepam (a benzodiazepine) but without sedation, cognitive impairment, or withdrawal symptoms
• Response rate was approximately 68% in the Selank group versus 34% in the placebo group

Cognitive Enhancement:

• Studies in patients with cognitive impairment from anxiety and chronic stress showed improved memory consolidation, attention span, and verbal fluency after 2-4 weeks of Selank use
• A study of healthy volunteers showed improved short-term memory and information processing speed
• EEG studies demonstrated increased alpha-wave activity (associated with relaxed alertness) and improved cortical information processing

Neurasthenia:

• Clinical trials in patients with neurasthenia (chronic fatigue and cognitive exhaustion from prolonged stress) showed significant improvement in energy, motivation, and cognitive function
• Effects were sustained during the treatment period without tolerance development

Comparative Studies:

• In a head-to-head comparison with phenazepam (a potent benzodiazepine widely used in Russia), Selank showed comparable anxiolytic efficacy for mild-to-moderate anxiety with dramatically fewer side effects
• No sedation, no psychomotor impairment, no memory disruption, and no dependence after abrupt discontinuation

Preclinical Research

Animal studies have further characterized Selank’s pharmacology:

• Anxiolytic effects confirmed in elevated plus maze, light-dark box, and social interaction tests
• No withdrawal syndrome after chronic administration and abrupt cessation
• No tolerance development over extended dosing periods in most models
• Neuroprotective effects demonstrated in ischemia and neurotoxicity models
• Enhanced learning in Morris water maze and passive avoidance conditioning

Limitations of Current Research

• Most clinical data comes from Russian studies, which may use different methodology standards than Western regulatory agencies require
• Studies are often relatively small (30-100 subjects)
• Limited independent replication outside of Russian research institutions
• Long-term safety data (beyond 12 months) is sparse
• Dose-response relationships are not fully characterized across all populations
• Western regulatory review (FDA, EMA) has not been sought or completed
• Publication bias cannot be excluded, as negative results may be underreported

Benefits of Selank

Anxiolytic Effects

The primary clinical application:

• Rapid anxiety reduction: Effects noticeable within 15-30 minutes of intranasal administration
• No sedation: Unlike benzodiazepines, Selank reduces anxiety while maintaining or enhancing mental clarity
• No cognitive impairment: Memory and executive function are preserved or improved
• No physical dependence: No withdrawal syndrome upon discontinuation
• No muscle relaxation: Maintains normal muscle tone and motor coordination
• Generalized and situational anxiety: Effective for both chronic anxiety and acute situational stress

Cognitive Enhancement

• Improved focus and attention: Enhanced ability to sustain concentration on tasks
• Better memory consolidation: Improved transfer of short-term to long-term memory
• Verbal fluency: Some users report improved word-finding and articulation
• Mental clarity: Reduced “brain fog” particularly in individuals with stress-related cognitive impairment
• Information processing: Faster cognitive processing speed in some studies

Mood Stabilization

• Emotional regulation: More stable emotional responses to stressors
• Mild antidepressant effect: Through serotonin and enkephalin modulation
• Stress resilience: Enhanced ability to cope with psychosocial stressors
• Reduced irritability: Reported by many users, particularly during periods of high stress

Immune Support

• Enhanced innate immunity: Particularly relevant during periods of chronic stress
• Antiviral activity: Documented in preclinical research, including against influenza
• Reduced illness frequency: Some users report fewer colds and infections during Selank use

Comparison to Benzodiazepines

Dosing Protocols

Standard Anxiolytic Protocol

Cognitive Enhancement Protocol

Acute Stress/Situational Protocol

Administration Technique

Proper intranasal administration is important for consistent absorption:

1. Clear nasal passages before administration (gentle blow or saline rinse)
2. Tilt head slightly forward (not back — this prevents solution from running into the throat)
3. Insert tip into nostril and aim toward the outer wall (turbinates), not the septum
4. Administer one spray/drop into each nostril (total dose split between nostrils)
5. Inhale gently through the nose after administration
6. Avoid blowing nose for at least 10 minutes after dosing
7. Alternate dominant nostril if using drops to ensure even mucosal exposure

Side Effects

Common (generally mild)

• Mild nasal irritation: Slight tingling or dryness in the nasal passages
• Transient fatigue: Some users report brief tiredness in the first few days of use, which typically resolves
• Light headache: Occasionally reported during initial use

Uncommon

• Mild allergic reaction: Nasal congestion, sneezing, or runny nose
• Dizziness: Transient, usually resolves within minutes
• Appetite changes: Slight increase or decrease in appetite

Notable Absences

What distinguishes Selank from most anxiolytics is the absence of common side effects:

• No sedation or drowsiness
• No cognitive impairment or memory disruption
• No motor incoordination
• No physical dependence or withdrawal
• No sexual dysfunction (unlike SSRIs)
• No weight gain (unlike many psychiatric medications)
• No emotional blunting (unlike benzodiazepines and some SSRIs)

Who Should NOT Use Selank

• Individuals with known hypersensitivity to tuftsin or Selank
• Pregnant or breastfeeding women (insufficient safety data)
• Individuals with severe nasal obstruction or conditions preventing intranasal absorption
• Those on multiple psychiatric medications without physician guidance
• Individuals with autoimmune disorders (due to immunomodulatory effects — consult a physician)

Synergistic Combinations

Selank + Semax

The classic Russian nootropic stack:

• Selank provides the anxiolytic/calming component
• Semax provides the stimulating/cognitive-enhancing component
• Together they create a balanced state of calm focus
• Use Selank in the morning and afternoon; add Semax in the morning and early afternoon
• The combination addresses both emotional regulation and cognitive performance

Selank + L-Theanine

• L-Theanine (100-200mg) promotes alpha-wave brain activity and calm alertness
• Both compounds reduce anxiety without sedation through different mechanisms
• Selank modulates GABA and serotonin at the peptide/receptor level; L-Theanine modulates glutamate
• The combination provides layered anxiolysis that many users find superior to either alone
• L-Theanine can be taken in the morning with coffee for a calm, focused state complemented by Selank

Selank + Magnesium

• Magnesium (200-400mg glycinate or threonate) is a natural GABA modulator and NMDA receptor antagonist
• Selank enhances GABA receptor sensitivity; magnesium provides the mineral cofactor for optimal GABA function
• Magnesium threonate (Magtein) specifically crosses the blood-brain barrier for direct CNS effects
• Evening magnesium supports sleep quality; daytime Selank supports waking anxiolysis
• Together they create comprehensive GABAergic support

Storage and Handling

Nasal Spray Solution

• Store refrigerated (2-8C / 36-46F) after opening
• Shelf life: Typically 30-45 days after first use when refrigerated
• Protect from light: Keep in original container or wrap in foil
• Do not freeze: Freezing may damage the peptide structure
• Check for clarity: Discard if solution becomes cloudy or discolored

Lyophilized Powder (if reconstituting)

• Unreconstituted: Stable refrigerated for months, room temperature for weeks
• Reconstitution: Use bacteriostatic water or saline as specified by supplier
• After reconstitution: Refrigerate and use within 30-45 days

Legal Status

Selank is currently:

• Approved for medical use in Russia (prescription anxiolytic and nootropic)
• NOT FDA-approved in the United States
• NOT approved by the EMA in Europe
• Available as a research chemical in many Western countries
• Sold as a “research peptide” by various online suppliers
• Not a controlled substance in most jurisdictions (but verify local regulations)
• Not banned by WADA as of current listings

Important regulatory note: The legal status of Selank for personal use varies significantly by country. In some jurisdictions, purchasing research peptides for personal use occupies a legal gray area. Always verify the regulations in your specific location before purchasing or using Selank.

Frequently Asked Questions

How quickly does Selank work for anxiety?

The acute anxiolytic effects are typically felt within 15-30 minutes of intranasal administration. However, the full cognitive-enhancing and mood-stabilizing benefits develop over 1-2 weeks of consistent daily use as BDNF upregulation and neuroplastic changes take effect.

Can Selank replace my benzodiazepine?

Selank may be a viable alternative for individuals with mild-to-moderate anxiety, but it should not be considered equivalent in potency to benzodiazepines for severe anxiety or panic disorder. Never abruptly discontinue benzodiazepines — this can cause dangerous withdrawal including seizures. Any transition should be managed by a qualified physician with a gradual taper plan.

Does Selank cause dependence?

No physical dependence or withdrawal syndrome has been documented in clinical research or post-marketing surveillance in Russia. This is one of Selank’s primary advantages over traditional anxiolytics. However, psychological reliance on any anxiolytic compound is possible, and periodic breaks are recommended.

Can I use Selank with an SSRI?

Selank modulates serotonin signaling, so there is a theoretical interaction with SSRIs. In practice, the combination has been used, but it should be done under medical supervision. The risk of serotonin syndrome is considered low based on Selank’s mechanism, but caution is warranted.

Why is most Selank research from Russia?

Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, and the Russian pharmaceutical industry pursued its clinical development and regulatory approval. Western pharmaceutical companies have not pursued FDA or EMA approval, likely because peptide therapeutics face challenges in patent protection and the regulatory pathway for novel anxiolytics is lengthy and expensive.

Is the nasal spray form effective?

Yes. Intranasal delivery is the primary and most effective route for Selank. The nasal mucosa provides a direct pathway to the CNS via the olfactory nerve, bypassing the blood-brain barrier. This results in rapid onset and high brain bioavailability relative to systemic administration.

Medical Disclaimer

This article is provided for educational and informational purposes only. Selank is a research peptide that is not approved by the FDA or EMA for human use. It is approved in Russia as a prescription medication. The information presented here does not constitute medical advice, and no doctor-patient relationship is implied. Always consult with a qualified healthcare provider before using any peptide or research compound, especially if you are currently taking psychiatric medications. Selank should not be used as a substitute for professional mental health treatment. Self-treatment of anxiety disorders carries risks, and proper diagnosis and treatment by a qualified professional is always recommended.